| Phenomapping of patients with heart failure with preserved ejection fraction using machine learning‐based unsupervised cluster analysis MW Segar, KV Patel, C Ayers, M Basit, WHW Tang, D Willett, J Berry, ... European journal of heart failure 22 (1), 148-158, 2020 | 221 | 2020 |
| Machine learning to predict the risk of incident heart failure hospitalization among patients with diabetes: the WATCH-DM risk score MW Segar, M Vaduganathan, KV Patel, DK McGuire, J Butler, ... Diabetes care 42 (12), 2298-2306, 2019 | 212 | 2019 |
| TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells H Cardenas, E Vieth, J Lee, M Segar, Y Liu, KP Nephew, D Matei Epigenetics 9 (11), 1461-1472, 2014 | 184 | 2014 |
| Epigenetic targeting of ovarian cancer stem cells Y Wang, H Cardenas, F Fang, S Condello, P Taverna, M Segar, Y Liu, ... Cancer research 74 (17), 4922-4936, 2014 | 165 | 2014 |
| Deep-learning models for the echocardiographic assessment of diastolic dysfunction A Pandey, N Kagiyama, N Yanamala, MW Segar, JS Cho, M Tokodi, ... Cardiovascular Imaging 14 (10), 1887-1900, 2021 | 88 | 2021 |
| Development and validation of machine learning–based race-specific models to predict 10-year risk of heart failure: a multicohort analysis MW Segar, BC Jaeger, KV Patel, V Nambi, CE Ndumele, A Correa, ... Circulation 143 (24), 2370-2383, 2021 | 86 | 2021 |
| Gender-based differences in outcomes among resuscitated patients with out-of-hospital cardiac arrest P Mody, A Pandey, AS Slutsky, MW Segar, A Kiss, P Dorian, J Parsons, ... Circulation 143 (7), 641-649, 2021 | 72 | 2021 |
| Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer M de Leon, H Cardenas, E Vieth, R Emerson, M Segar, Y Liu, K Nephew, ... Gynecologic oncology 142 (3), 539-547, 2016 | 63 | 2016 |
| Frailty status modifies the efficacy of exercise training among patients with chronic heart failure and reduced ejection fraction: an analysis from the HF-ACTION trial A Pandey, MW Segar, S Singh, GR Reeves, C O’Connor, I Piña, ... Circulation 146 (2), 80-90, 2022 | 57 | 2022 |
| Association of long-term change and variability in glycemia with risk of incident heart failure among patients with type 2 diabetes: a secondary analysis of the ACCORD trial MW Segar, KV Patel, M Vaduganathan, MC Caughey, J Butler, ... Diabetes care 43 (8), 1920-1928, 2020 | 54 | 2020 |
| Generalizability and Implications of the H2FPEF Score in a Cohort of Patients With Heart Failure With Preserved Ejection Fraction: Insights From the TOPCAT Trial MW Segar, KV Patel, JD Berry, JL Grodin, A Pandey Circulation 139 (15), 1851-1853, 2019 | 52 | 2019 |
| Rifampin regulation of drug transporters gene expression and the association of microRNAs in human hepatocytes EA Benson, MT Eadon, Z Desta, Y Liu, H Lin, KS Burgess, MW Segar, ... Frontiers in pharmacology 7, 111, 2016 | 47 | 2016 |
| Machine learning–based models incorporating social determinants of health vs traditional models for predicting in-hospital mortality in patients with heart failure MW Segar, JL Hall, PS Jhund, TM Powell-Wiley, AA Morris, D Kao, ... JAMA cardiology 7 (8), 844-854, 2022 | 46 | 2022 |
| Prevalence and prognostic implications of diabetes with cardiomyopathy in community-dwelling adults MW Segar, MS Khan, KV Patel, J Butler, WHW Tang, M Vaduganathan, ... Journal of the American College of Cardiology 78 (16), 1587-1598, 2021 | 46 | 2021 |
| Supranormal left ventricular ejection fraction, stroke volume, and cardiovascular risk: findings from population-based cohort studies S Shah, MW Segar, N Kondamudi, C Ayers, A Chandra, S Matulevicius, ... Heart Failure 10 (8), 583-594, 2022 | 45 | 2022 |
| Frailty, guideline-directed medical therapy, and outcomes in HFrEF: from the GUIDE-IT trial MS Khan, MW Segar, MS Usman, S Singh, SJ Greene, GC Fonarow, ... Heart Failure 10 (4), 266-275, 2022 | 40 | 2022 |
| Age‐related changes in MicroRNA expression and pharmacogenes in human liver KS Burgess, S Philips, EA Benson, Z Desta, A Gaedigk, R Gaedigk, ... Clinical Pharmacology & Therapeutics 98 (2), 205-215, 2015 | 40 | 2015 |
| Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia MW Segar, MS Khan, KV Patel, M Vaduganathan, V Kannan, D Willett, ... European journal of heart failure 24 (1), 169-180, 2022 | 33 | 2022 |
| Association of genetic West African ancestry, blood pressure response to therapy, and cardiovascular risk among self-reported black individuals in the Systolic Blood Pressure … S Rao, MW Segar, AP Bress, P Arora, W Vongpatanasin, V Agusala, ... JAMA cardiology 6 (4), 388-398, 2021 | 32 | 2021 |
| Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus MW Segar, AA Kolkailah, R Frederich, A Pong, CP Cannon, F Cosentino, ... Diabetes, Obesity and Metabolism 24 (9), 1829-1839, 2022 | 31 | 2022 |
Ambarish PandeyUniversity of Texas Southwestern Medical Center, DallasVerifisert e-postadresse på utsouthwestern.edu